Just when investors were getting jittery that SkyePharma PLC might not attain its well-publicized goal of reaching profitability in 2002, the drug delivery/product development company announced an end-of-year deal with Endo Pharmaceuticals Inc. that analysts think will almost certainly put it in the black [See Deal]. Endo licensed the US and Canadian rights to SkyePharma's highest profile development candidates: DepoMorphine, a Phase III sustained-release morphine injection for post-operative pain, and Propofol IDD-DTM, its Phase IIb nanoparticle formulation of the injected hospital anesthetic propofol. In exchange, SkyePharma received a $25 million (£15.3 million) upfront payment and could get another $95 million in regulatory and sales milestones.
SkyePharma, which will bear primary responsibility for continued development and manufacturing, is also entitled to a percentage of each product's...




